IU School of Medicine researcher Dr. Bryan Schneider is leading a new nationwide clinical trial to improve cure rates for patients with triple-negative breast cancer. 

PERSEVERE, a phase 2 clinical trial, is designed to better understand the effectiveness of personalized cancer treatments based on patients’ genetic makeup. 

Read the full article at www.idsnews.com